|Title:||Treating myocardial infarction by administration of a thrombolytic agent together with adenosine|
|Abstract:||This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL) and in radionucleide scintography.|
|Inventor(s):||Sollevi; Alf (Bromma, SE)|
|Assignee:||Item Development (Stocksund, SE)|
|Filing Date:||Dec 21, 1994|
|Claims:||1. In a method for coronary thrombolysis (CTL), treatment of acute myocardial infarction in a human patient by administration of thrombolytic substance having an ability to dissolve a blood clot in the coronary circulation, the improvement of simultaneously administering adenosine by continuous infusion into the blood stream of said patient to lessen negative effects of said CTL. |
2. A method as claimed in claim 1 wherein adenosine is administered intravenously at a rate of 10-100 micrograms of adenosine per kilogram bodyweight per minute.
3. A method as claimed in claim 1 wherein adenosine is administered directly into the coronary circulation at a rate of 5-30 microgram of adenosine per kilogram bodyweight per minute.
4. A method as claimed in claim 1 wherein adenosine is administered in admixture with the thrombolytic agent.
5. A solution for intravascular administration in treatment of acute myocardial infarction in a human patient, said solution comprising an effective amount of a thrombolytic substance having an ability to dissolve a blood clot in the coronary circulation and adenosine in an amount effective to prevent re-occlusion of initially occluded vessels.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.